CDKN2A/P16-INK4A Rekombinanter Antikörper
CDKN2A/P16-INK4A Rekombinant Antikörper für WB, IHC, IF/ICC, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IHC, IF/ICC, Indirect ELISA
Konjugation
Unkonjugiert
CloneNo.
241438C7
Kat-Nr. : 81373-8-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
81373-8-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA CDKN2A/P16-INK4A und zeigt Reaktivität mit human
Getestete Reaktivität | human |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Rekombinant |
Typ | Antikörper |
Immunogen | CDKN2A/P16-INK4A fusion protein Ag1328 |
Vollständiger Name | cyclin-dependent kinase inhibitor 2A |
Berechnetes Molekulargewicht | 16 kDa |
Beobachtetes Molekulargewicht | 16 kDa |
GenBank-Zugangsnummer | BC021998 |
Gene symbol | CDKN2A |
Gene ID (NCBI) | 1029 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Protein-A-Reinigung |
Lagerungspuffer | PBS only |
Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively-spliced variants encoding distinct proteins proteins were reported. Two of them named p16-INK4 and p14 are sharing 50% identity. P16 plays an essential role in regulating the cell cycle, and mutations in p16 increase the risk of developing various cancers, including melanoma. Long-term p16(INK4a) expression pushes cells to enter senescence, an irreversible cell-cycle arrest that precludes the growth of would-be cancer cells but also contributes to cellular aging (PMID: 24136988).